Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in brain and periphery. Augmentation with drugs that lower this pro-inflammatory status may improve clinical presentation. Simvastatin crosses the blood-brain barrier, has anti- inflammatory and neuroprotective effects and reduces metabolic syndrome. In this study, we investigated if 12 months of simvastatin augmentation can improve symptoms and cognition in patients with early SSD. This double-blind placebo-controlled trial included 127 SSD patients across the Netherlands, <3 years after their diagnosis. From these, 119 were randomly assigned 1:1 to simvastatin 40 mg (n = 61) or placebo (n = 58), stratified for sex and study site. Primary out...
Background Accumulating evidence shows that a propensity towards a pro-inflammatory status in the br...
BackgroundThe symptom severity of a substantial group of schizophrenia patients (30-40%) does not im...
OBJECTIVE: Immune dysregulation may be involved in the pathophysiology of schizophrenia. Given the n...
Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in b...
Item does not contain fulltextSchizophrenia-spectrum disorders (SSD) are associated with increased i...
Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in b...
Introduction: Statins such as simvastatin are recently introduced as agents that may have beneficial...
Background: There is ample evidence that inflammatory processes play a role in the pathophysiology o...
Background: There is ample evidence that inflammatory processes play a role in the pathophysiology o...
Immune dysregulation has been reported in schizophrenia spectrum disorders (SSD). In the past decade...
Background: Findings from both epidemiological and basic research point to the possibility that NSAI...
Background Accumulating evidence shows that a propensity towards a pro-inflammatory status in the br...
BackgroundThe symptom severity of a substantial group of schizophrenia patients (30-40%) does not im...
OBJECTIVE: Immune dysregulation may be involved in the pathophysiology of schizophrenia. Given the n...
Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in b...
Item does not contain fulltextSchizophrenia-spectrum disorders (SSD) are associated with increased i...
Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in b...
Introduction: Statins such as simvastatin are recently introduced as agents that may have beneficial...
Background: There is ample evidence that inflammatory processes play a role in the pathophysiology o...
Background: There is ample evidence that inflammatory processes play a role in the pathophysiology o...
Immune dysregulation has been reported in schizophrenia spectrum disorders (SSD). In the past decade...
Background: Findings from both epidemiological and basic research point to the possibility that NSAI...
Background Accumulating evidence shows that a propensity towards a pro-inflammatory status in the br...
BackgroundThe symptom severity of a substantial group of schizophrenia patients (30-40%) does not im...
OBJECTIVE: Immune dysregulation may be involved in the pathophysiology of schizophrenia. Given the n...